Valuation: Verastem, Inc.

Market Cap 516M 447M 416M 383M 723M 49.05B 731M 4.89B 1.92B 24.54B 1.94B 1.89B 81.28B P/E 2026 *
-3.71x
P/E 2027 * -5.23x
Enterprise Value 351M 304M 283M 261M 492M 33.36B 497M 3.33B 1.31B 16.69B 1.32B 1.29B 55.28B EV / Sales 2026 *
3.44x
EV / Sales 2027 * 1.72x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+1.03%
1 week-2.33%
Current month+1.21%
1 month+30.44%
3 months-1.51%
6 months-6.53%
Current year-23.96%
1 week 5.54
Extreme 5.54
6.09
1 month 4.3
Extreme 4.3
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+1.03%-2.33%-1.68%-47.40% 516M
+4.35%+16.60%+58.11%+95.21% 64.9B
+2.83%-3.48%+24.97%+67.25% 54.05B
+0.91%-0.83%-17.01%-13.43% 23.16B
+0.27%-3.98%-11.28%+350.30% 21.46B
+1.77%+9.15%+30.49%-5.91% 21.25B
+0.75%+1.34%+32.22%-25.25% 17.94B
+9.88%+23.61%+222.87%+385.49% 17.03B
+2.38%+4.68%+19.94%+629.71% 14.99B
+1.25%+2.48%+51.36%+179.72% 14.25B
Average +2.52%+4.30%+41.00%+161.57% 24.95B
Weighted average by Cap. +2.93%+5.89%+42.22%+140.18%

Financials

2026 *2027 *
Net sales 102M 88.23M 82.25M 75.65M 143M 9.69B 144M 966M 379M 4.85B 383M 374M 16.05B 178M 154M 144M 132M 250M 16.96B 253M 1.69B 664M 8.49B 670M 655M 28.1B
Net income -166M -143M -134M -123M -232M -15.74B -235M -1.57B -616M -7.88B -622M -608M -26.08B -142M -123M -115M -105M -199M -13.51B -201M -1.35B -529M -6.76B -534M -522M -22.39B
Net Debt -165M -143M -133M -123M -231M -15.69B -234M -1.57B -614M -7.85B -620M -606M -26B -210M -182M -169M -156M -294M -19.93B -297M -1.99B -780M -9.97B -787M -770M -33.03B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
05/08/26 USD 5.870 +1.03% 1,554,979
04/08/26 USD 5.810 +2.11% 1,791,796
03/08/26 USD 5.690 -1.90% 1,288,075
31/07/26 USD 5.800 -4.92% 1,857,262
30/07/26 USD 6.100 +1.50% 1,451,955
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.870USD
Average target price
15.00USD
Spread / Average Target
+155.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock